[Management of the thrombotic risk associated with COVID-19: what is the role of the hemostasis laboratory?] / Apport du laboratoire d'hémostase dans la gestion du risque thrombotique associé au Covid-19.
Ann Biol Clin (Paris)
; 78(5): 471-481, 2020 10 01.
Article
in French
| MEDLINE | ID: covidwho-836030
ABSTRACT
COVID-19 is associated with disturbances of hemostasis in the laboratory and an increased thrombotic risk. Routine laboratory tests - activated partial thromboplastin time (aPTT), prothrombin time, Clauss fibrinogen and D-dimers levels measurement - are used for the evaluation of the thrombotic risk and the monitoring of hemostasis, but are subject to several drawbacks that may affect the reliability and clinical relevance of the delivered results. Another challenge for the hemostasis laboratory is the monitoring of heparin treatment. For instance, the issue of the monitoring of unfractionated heparin remains debated, the more so when there is a tremendous inflammatory response. This brief review considers the role of laboratory tests of hemostasis in the management of COVID-19 and discusses their main limitations to be kept in mind.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Thrombosis
/
Coronavirus Infections
/
Hemostasis
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
French
Journal:
Ann Biol Clin (Paris)
Year:
2020
Document Type:
Article
Affiliation country:
Abc.2020.1581
Similar
MEDLINE
...
LILACS
LIS